SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes.

SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes.

Show other versions (1)

<h4>Introduction</h4>Cardiovascular disease (CVD) is two to five times more prevalent in diabetic patients and is the leading cause of death. Therefore, identification of novel therapeutic strategies that reduce the risk of CVD is a research priority. Clinical trials showed that reductio...

Full description

Bibliographic Details
Main Authors: Judit Hodrea, Adar Saeed, Agnes Molnar, Attila Fintha, Adrienn Barczi, Laszlo J Wagner, Attila J Szabo, Andrea Fekete, Dora B Balogh
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0263285

Similar Items

Similar Items